Dale Stephen's most recent trade in Sysco Corp. was a trade of 220 Common Stock done at an average price of $74.7 . Disclosure was reported to the exchange on May 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sysco | Stephen Dale Higgs | SVP | Exercise or conversion of derivative security received from the company (such as an option) at price $ 74.71 per share. | 01 May 2026 | 220 | 8,154 (0%) | 0% | 74.7 | 16,436 | Common Stock |
| Sysco | Stephen Dale Higgs | SVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.71 per share. | 01 May 2026 | 87 | 8,067 (0%) | 0% | 74.7 | 6,500 | Common Stock |
| Legence Corp Ordinary | Stephen Dale Hansen | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2026 | 15,343 | 15,343 | - | - | Employee Stock Options | |
| Legence Corp Ordinary | Stephen Dale Hansen | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2026 | 8,298 | 25,262 | - | 0 | Class A Common Stock | |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.55 per share. | 29 Jan 2024 | 4,825 | 38,817 (0%) | 0% | 21.6 | 103,980 | Common Stock |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.80 per share. | 29 Jan 2024 | 4,400 | 46,400 (0%) | 0% | 17.8 | 78,322 | Common Stock |
| Kura Oncology Inc | Dale Stephen | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.80 per share. | 29 Jan 2024 | 2,758 | 43,642 (0%) | 0% | 17.8 | 49,094 | Common Stock |
| Kura Oncology Inc | Dale Stephen | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 185,000 | 185,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 185,000 | 185,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 23,125 | 50,800 (0%) | 0% | 0 | Common Stock | |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.87 per share. | 27 Jan 2023 | 4,840 | 27,675 (0%) | 0% | 13.9 | 67,124 | Common Stock |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 27 Jan 2023 | 4,385 | 32,515 (0%) | 0% | 13.9 | 60,909 | Common Stock |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 261,000 | 261,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Stephen Dale | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 36,900 | 36,900 (0%) | 0% | 0 | Common Stock |